Clinical Trials Browser

Completed × Neoplasms × cediranib × Clear all

NCT00321581 2019-11-21

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Phase 1 Completed

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Phase 2 Completed

105 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT00777153 2016-12-28

REGAL

Phase 3 Completed

423 enrolled 13 charts

Glioblastoma, Neoplasms

NCT00306891 2012-11-01

Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)

Phase 2 Completed

60 enrolled 13 charts

Neoplasms

NCT00385203 2012-07-16

The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).

Phase 2 Completed

35 enrolled 13 charts

GastrointestinalSarcoma

Neoplasms, Sarcoma, Gastrointestinal Stromal Tumors

NCT00748891 2011-07-01

DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)

Phase 1 Completed

Neoplasms

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT00503204 2009-11-25

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Neoplasms